Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 15/20 | 0.46 |
| ▸ | CSF1R | P07333 | 10/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | KIT | P10721 | 3/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335421 | 0.83 | PIM1 (0.69) | PIM1IRAK4KDRFLT3PIM3 | |
| SCHEMBL3335751 | 0.83 | KDR (0.57) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL3333163 | 0.82 | PIM1 (0.50) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL3332573 | 0.82 | PIM1 (0.52) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL3331017 | 0.80 | KDR (0.72) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL3335331 | 0.80 | KDR (0.49) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL3333936 | 0.80 | PIM1 (0.48) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL30440917 | 0.77 | FLT3 (0.59) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL27030689 | 0.77 | FLT3 (0.59) | PIM1IRAK4KDRCSF1RFLT3 | |
| SCHEMBL3331016 | 0.75 | KDR (0.68) | KDRCSF1RFLT3KITCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | PIM1 1/4885IRAK4 29/4885KDR 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.